| Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. | |
| | |
MedLine Citation:
|
PMID: 21690327 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Multiple autoimmune diseases are characterized by the involvement of autoreactive Abs in pathogenesis. Problems associated with existing therapeutics such as the delivery of intravenous immunoglobulin have led to interest in developing alternative approaches using recombinant or synthetic methods. Toward this aim, in the current study, we demonstrate that the use of Fc-engineered Abs (Abs that enhance IgG degradation [Abdegs]) to block neonatal FcR (FcRn) through high-affinity, Fc region binding is an effective strategy for the treatment of Ab-mediated disease. Specifically, Abdegs can be used at low, single doses to treat disease in the K/B×N serum transfer model of arthritis using BALB/c mice as recipients. Similar therapeutic effects are induced by 25- to 50-fold higher doses of i.v. Ig. Importantly, we show that FcRn blockade is a primary contributing factor toward the observed reduction in disease severity. The levels of albumin, which is also recycled by FcRn, are not affected by Abdeg delivery. Consequently, Abdegs do not alter FcRn expression levels or subcellular trafficking behavior. The engineering of Ab Fc regions to generate potent FcRn blockers therefore holds promise for the therapy of Ab-mediated autoimmunity. |
| | |
Authors:
|
Dipesh A Patel; Alberto Puig-Canto; Dilip Kumar Challa; Héctor Perez Montoyo; Raimund J Ober; E Sally Ward |
Related Documents
:
|
23101977 - Immunology in alcoholic liver disease. 21676237 - Predictors for pathologically confirmed aortitis after resection of the ascending aorta... 20478487 - Endoscopic ultrasonography in diseases of the gallbladder. 21550817 - Worldwide clinical interventional studies on leading causes of death: a descriptive ana... 9754957 - Astrocytic pathology in progressive supranuclear palsy: significance for neuropathologi... 20939257 - Screening of chronic diseases and chronic disease risk factors in two rural communities... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural Date: 2011-06-20 |
Journal Detail:
|
Title: Journal of immunology (Baltimore, Md. : 1950) Volume: 187 ISSN: 1550-6606 ISO Abbreviation: J. Immunol. Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-07-07 Completed Date: 2011-09-23 Revised Date: 2012-07-17 |
Medline Journal Info:
|
Nlm Unique ID: 2985117R Medline TA: J Immunol Country: United States |
Other Details:
|
Languages: eng Pagination: 1015-22 Citation Subset: AIM; IM |
Affiliation:
|
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9093, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Inflammatory Agents, Non-Steroidal / metabolism, therapeutic use Antibodies, Blocking / genetics, metabolism, therapeutic use Antibody Affinity* / genetics Arthritis, Experimental / immunology*, pathology, therapy* Glucose-6-Phosphate Isomerase / immunology Histocompatibility Antigens Class I / metabolism Humans Immunoglobulin Fc Fragments / genetics, metabolism, therapeutic use* Immunoglobulin G / genetics, metabolism, therapeutic use Mice Mice, Inbred BALB C Mice, Inbred NOD Mice, Transgenic Protein Engineering / methods* Receptors, Antigen, T-Cell, alpha-beta / genetics, immunology, metabolism Receptors, Fc / antagonists & inhibitors*, deficiency, metabolism Recombinant Proteins / chemical synthesis, metabolism, therapeutic use Severity of Illness Index |
| Grant Support | |
ID/Acronym/Agency:
|
R01 AI 39167/AI/NIAID NIH HHS; R01 AI039167-12/AI/NIAID NIH HHS; R01 AR 56478/AR/NIAMS NIH HHS; R01 AR056478-03/AR/NIAMS NIH HHS; R01 AR056478-05/AR/NIAMS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies, Blocking; 0/Fc receptor, neonatal; 0/Histocompatibility Antigens Class I; 0/Immunoglobulin Fc Fragments; 0/Immunoglobulin G; 0/Receptors, Antigen, T-Cell, alpha-beta; 0/Receptors, Fc; 0/Recombinant Proteins; 0/T cell receptor Vbeta6, human; EC 5.3.1.9/Glucose-6-Phosphate Isomerase |
| Comments/Corrections | |
Comment In:
|
Nat Rev Rheumatol. 2011 Sep;7(9):496
[PMID:
21769129
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Simulations of the NK Cell Immune Synapse Reveal that Activation Thresholds Can Be Established by In...
Next Document: Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors.